Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS).

被引：1
|
作者：
Carril, Lucia
Colomba, Emeline
Romero-Ferreiro, Carmen
Cerbone, Luigi
Ratta, Raffaele
Barthelemy, Philippe
Vindry, Clarisse
Cherifi, Francois
Boughalem, Elouen
Linassier, Claude
Fornarini, Giuseppe
Gross-Goupil, Marine
Saldana, Carolina
Soberon, Maria Cruz Martin
de Velasco, Guillermo
Pernaut, Cristina
Silva, Carolina Alves Costa
Flippot, Ronan
Escudier, Bernard
Albiges, Laurence
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Gustave Roussy Cancerol Inst, Villejuif, France
[3] Univ Hosp 12 Octubre, Madrid, Spain
[4] Gustave Roussy, Dept Med Oncolog, Villejuif, France
[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[6] Inst Cancerol Strasbourg Europe, Strasbourg, France
[7] Leon Bernard Ctr, Lyon, France
[8] Ctr Francois Baclesse, Caen, France
[9] Ctr Paul Papin, Angers, France
[10] Tours Univ, CHU Bretonneau Ctr, Dept Med Oncol, Tours, France
[11] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
[12] Ctr Hosp Univ, Bordeaux Hop St Andre, Bordeaux, France
[13] AP HP Henri Mondor Hosp, Creteil, France
[14] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[15] Hosp 12 Octubre, Dept Oncol, Madrid, Spain
[16] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[17] Inst Gustave Roussy, Villejuif, France
[18] Gustave Roussy Canc Campus, Villejuif, France
[19] Gustave Roussy, Villejuif, France
[20] Univ Paris Saclay, Gustave Roussy Canc Campus, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.320
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
320
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [2] Comparative effectiveness of combination first-line therapies for metastatic renal cell carcinoma (mRCC).
    Shay, Rebecca C.
    Nicklawsky, Andrew
    Lam, Elaine Tat
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Tolerability of different first-line treatment (trt) regimens in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC)
    Mueller, L.
    Muench, A.
    Blumenstengel, K.
    Hutzschenreuther, U.
    Busies, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features
    Barroso-Sousa, Romualdo
    Munhoz, Rodrigo Ramella
    Fonseca, Leonardo Gomes
    de Sousa Fede, Angelo Bezerra
    Marques Linck, Rudinei Diogo
    Venchiarutti Moniz, Camila Motta
    Mak, Milena Perez
    Souza, Ciro Eduardo
    Hoff, Paulo M.
    Dzik, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [5] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Shiva Gupta
    Hyunseon C. Kang
    Jia Sun
    Marc R. Matrana
    Nizar M. Tannir
    Haesun Choi
    [J]. Abdominal Radiology, 2020, 45 : 1872 - 1882
  • [6] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Gupta, Shiva
    Kang, Hyunseon C.
    Sun, Jia
    Matrana, Marc R.
    Tannir, Nizar M.
    Choi, Haesun
    [J]. ABDOMINAL RADIOLOGY, 2020, 45 (06) : 1872 - 1882
  • [8] Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC)
    Jonasch, E.
    Bair, A.
    Chen, Y.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A PHASE IV MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE THERAPY IN CHINESE PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Qin, S.
    Jin, J.
    Guo, J.
    Wang, J.
    Zhou, F.
    Huang, Y.
    Ren, X.
    Ye, D.
    Wang, Q.
    Pan, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 282 - 282
  • [10] Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
    Escudier, Bernard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1176 - 1178
12345